Journal of Renal Nutrition
Volume 19, Issue 5 , Pages 432-438 , September 2009

Sevelamer Hydrochloride Use and Circulating Endotoxin in Hemodialysis Patients: A Pilot Cross-Sectional Study

  • Phyllis P. Sun, MS, RD
    • ,
  • Mary C. Perianayagam, PhD
    • ,
  • Bertrand L. Jaber, MD, MS

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Bertrand L. Jaber, MD, MS, Division of Nephrology, Department of Medicine, Caritas St. Elizabeth's Medical Center, 736 Cambridge St., Boston, MA 02135.

References 

  1. Herselman M, Moosa MR, Kotze TJ, Kritzinger M, Wuister S, Mostert D. Protein-energy malnutrition as a risk factor for increased morbidity in long-term hemodialysis patients. J Ren Nutr. 2000;10:7–15
  2. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial. 2002;15:329–337
  3. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int. 2002;61(Suppl):S99–S102
  4. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469–476
  5. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899–1911
  6. Jaber BL, Pereira BJG. Inflammatory mediators in sepsis: rationale for extracorporeal therapies. Am J Kidney Dis. 1996;28(Suppl):S35–S49
  7. Genth-Zotz S, von Haehling S, Bolger AP, et al. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol. 2002;90:1226–1230
  8. Goncalves S, Pecoits-Filho R, Perreto S, et al. Fluid overload is associated with endotoxinemia but not with systemic inflammation in chronic kidney disease patients. [abstract] J Am Soc Nephrol. 2005;16:470A
  9. Water quality for dialysis. In: AAMI dialysis monogram series. 3rd ed.. Arlington, VA: Association for the Advancement of Medical Instrumentation; 1998;p. 1–64
  10. Arizono K, Nomura K, Motoyama T, et al. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif. 2004;22(Suppl 2):26–29
  11. Hsu PY, Lin CL, Yu CC, et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients—a prospective cross-over study. J Nephrol. 2004;17:693–700
  12. Magnusson M, Magnusson KE, Sundqvist T, Denneberg T. Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: effects of low- and high-protein diets. Nephron. 1990;56:306–311
  13. Magnusson M, Magnusson KE, Sundqvist T, Denneberg T. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut. 1991;32:754–759
  14. Kotanko P, Carter M, Levin NW. Intestinal bacterial microflora—a potential source of chronic inflammation in patients with chronic kidney disease. Nephrol Dial Transplant. 2006;21:2057–2060
  15. de Almeida Duarte JB, de Aguilar-Nascimento JE, Nascimento M, Nochi RJ. Bacterial translocation in experimental uremia. Urol Res. 2004;32:266–270
  16. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant. 1999;14:2907–2914
  17. Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther. 2003;10:133–145
  18. Braunlin W, Zhorov E, Guo A, et al. Bile acid binding to sevelamer HCl. Kidney Int. 2002;62:611–619
  19. De Smet R, Thermote F, Lameira N, et al. Sevelamer hydrochloride adsorbs the uremic compound indoxyl sulfate. [abstract] J Am Soc Nephrol. 2003;14:206A
  20. Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum. 2005;52:290–295
  21. Phan O, Ivanovski O, Nguyen-Khoa T, et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation. 2005;112:2875–2882
  22. Salusky IB. A new era in phosphate binder therapy: what are the options?. Kidney Int. 2006;105(Suppl):S10–S15
  23. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J. 2005;149:820–825
  24. Yamada K, Fujimoto S, Tokura T, et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail. 2005;27:361–365
  25. Perianayagam MC, Jaber BL. Endotoxin binding affinity of sevelamer hydrochloride. Am J Nephrol. 2008;28:802–807
  26. Bleeker WK, Kannegieter EM, Bakker JC, Loos JA. Endotoxin in blood products: correlation between the limulus assay and the rabbit pyrogen test. Prog Clin Biol Res. 1985;189:293–303
  27. Teehan GS, Guo D, Perianayagam MC, Balakrishnan VS, Pereira BJ, Jaber BL. Reprocessed (high-flux) polyflux dialyzers resist trans-membrane endotoxin passage and attenuate inflammatory markers. Blood Purif. 2004;22:329–337
  28. Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant. 1997;12:1640–1644
  29. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis. 1997;29:66–71
  30. Kang JY. The gastrointestinal tract in uremia. Dig Dis Sci. 1993;38:257–268
  31. Bratten JR, Jones MP. Small intestinal motility. Curr Opin Gastroenterol. 2007;23:127–133

 This investigator-initiated study was funded by a Research Grant from the National Kidney Foundation Council on Renal Nutrition (to P.P.S.) and a Research Grant from Genzyme Corp., Cambridge, MA (to B.L.J.).

PII: S1051-2276(09)00044-2

doi: 10.1053/j.jrn.2009.01.022

Journal of Renal Nutrition
Volume 19, Issue 5 , Pages 432-438 , September 2009

Article Tools

* Image Usage & Resolution